Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells

AIDS

Volumn 20, Issue 4, 2006, Pages 627-630

  Kran, Anne Marte B ^a   Sørensen, Birger ^b   Sommerfelt, Maja A ^b   Nyhus, Jørgen ^b   Baksaas, Ingebjørg ^c   Kvale, Dag ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b Bionor Immuno AS   (Norway)

^c Mericon   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PEPTIDE VACC 4X; UNCLASSIFIED DRUG; VIRUS PROTEIN; VACC 4X; VACC-4X;

ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG RESPONSE; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; LONG TERM CARE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; TREATMENT OUTCOME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; METHODOLOGY; PHYSIOLOGY; VIREMIA;

AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DENDRITIC CELLS; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; VIREMIA;

EID: 33645387291     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000210620.75707.ac     Document Type: Article

References (14)

1. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003; 21:265-304.
2. Calarota SA, Weiner DB. Present status of human HIV vaccine development. AIDS 2003; 17 (Suppl. 4):S73-S84.
3. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004; 10:806-810.
4. Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, Belyakov IM. Progress on new vaccine strategies against chronic viral infections. J Clin Invest 2004; 114:450-462.
5. Egan MA. Current prospects for the development of a therapeutic vaccine for the treatment of HIV type 1 infection. AIDS Res Hum Retrovir 2004; 20:794-806.
6. Lévy Y, Gahéry-Ségard H, Durier C, Lascaux A-S, Goujard C, Meiffredy V, et al. Immunological and virological efficiacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005; 19:279-286.
7. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10:1359-1365.
8. Kran AMB, Sørensen B, Nyhus J, Sommerfelt, Baksaas I, Bruun JN, Kvale D. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS 2004; 18:1875-1883.
9. Kran AMB, Sommerfelt MA, Sørensen B, Nyhus J, Baksaas I, Bruun JN, Kvale D. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization. Vaccine 2005; 23:4011-4015.
10. The British HIV Association. HIV treatment guidelines, update 2005. Available at: http://www.bhiva.org/guidelines/2005/BHIVA-guidelines/index.html. Accessed: 12 August 2005.
11. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, et al. Treatment for adult HIV infection. 2004 Recommendations of the International AIDS Society - USA panel. JAMA 2004; 292:251-265.
12. McNeil AC, Shupert WL, Iyasere CA, Hallahan CW, Mican JA, Davey RT Jr, Connors M. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci U S A 2001; 98:13878-13883.
13. Carcelain G, Tubiana R, Samri A, Calvez V, Delaugerre C, Agut H, et al. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol 2001; 75:234-241.
14. Kvale D, Kran AMB, Sommerfelt MA, Nyhus J, Baksaas I, Bruun JN, Sorensen B. Divergent in vitro and in vivo correlates of HIV-specific T cell responses during onset of HIV viremia. AIDS 2005; 19:563-567.